Dianthus Therapeutics (DNTH) Assets Average (2018 - 2025)

Dianthus Therapeutics' Assets Average history runs 8 years deep, the most recent figure standing at $554.2 million for Q4 2025.

• On a quarterly basis, Assets Average rose 52.19% year-over-year to $554.2 million in Q4 2025; TTM through Dec 2025 was $554.2 million, a 52.19% increase from a year earlier, with the FY2025 full-year figure at $452.5 million, up 63.52% from the prior year.
• Assets Average improved to $554.2 million in Q4 2025 per DNTH's latest filing, from $451.8 million in the prior quarter.
• Across five years, Assets Average topped out at $554.2 million in Q4 2025 and bottomed at $81.0 million in Q2 2023.
• The 5-year median for Assets Average is $195.1 million (2021), against an average of $249.5 million.
• Across the five-year window, Assets Average tumbled 56.66% in 2023 and jumped 363.61% in 2024, its largest moves.
• Year by year, Assets Average stood at $198.1 million in 2021, then tumbled by 37.59% to $123.6 million in 2022, then jumped by 50.41% to $185.9 million in 2023, then jumped by 95.84% to $364.1 million in 2024, then surged by 52.19% to $554.2 million in 2025.
• Per Business Quant, the three latest DNTH Assets Average figures stand at $554.2 million (Q4 2025), $451.8 million (Q3 2025), and $337.3 million (Q2 2025).